Antivenin (micrurus fulvius) - Biologic Drug Details

Summary for antivenin (micrurus fulvius)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antivenin (micrurus fulvius) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antivenin (micrurus fulvius) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for antivenin (micrurus fulvius) Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Antivenin (Micrurus fulvius)

Last updated: April 11, 2026

What are the current market drivers for Micrurus fulvius antivenin?

The antivenin targeting Micrurus fulvius, the eastern coral snake, primarily addresses envenomation cases in North America. The market is driven by factors including:

• Incidence rates: North America reports approximately 20 to 40 coral snake bites annually, with most cases in the southeastern United States. The low incidence limits broad market potential but sustains a niche segment.
• Regulatory landscape: The antivenin is classified as a biologic medicine, subject to FDA regulation. Approval for new formulations or manufacturing changes can influence market access.
• Medical necessity: The severity of coral snake envenomation justifies antivenin use. However, availability remains limited, especially outside the U.S.
• Manufacturing constraints: Production is complex due to the necessity of maintaining venom-specific antibody potency, with only a handful of suppliers globally.
• Demand fluctuations: Limited data indicates demand peaks during warmer months when snake activity increases and following awareness campaigns or adverse event reports.

How does the supply chain influence market stability?

The supply chain for Micrurus fulvius antivenin hinges on:

• Venom sourcing: Venom is extracted from captive coral snakes or collected in the wild, with a small pool of suppliers.
• Manufacturing complexity: Production involves immunizing animals, harvesting plasma, and purifying antibodies, which is labor-intensive and costly.
• Regulatory compliance: Strict adherence to Good Manufacturing Practices (GMP) impacts production continuity.
• Limited competitors: Few manufacturers hold FDA approval, resulting in market monopoly-like conditions and potential supply bottlenecks.

What is the financial outlook for antivenin targeting Micrurus fulvius?

The financial trajectory remains constrained by demand size and production costs:

Aspect	Details	Implication
Market Size	Estimated 20-40 cases annually in U.S.	Revenue potential limited
Pricing Strategy	Priced between $3,000 to $10,000 per vial (est.)	High per-unit revenue, low volume
Revenue Estimates	Assuming 30 cases/year at $7,500 per case, annual revenue of ~$225,000	Small market, limited revenue stream
R&D & Manufacturing Costs	High; estimates range from $10 million to $30 million for development and approval	Low profitability potential in current scope
Competitive Dynamics	One or two FDA-approved suppliers	Monopolistic margins possible

What are the key regulatory considerations affecting financial prospects?

Regulatory hurdles and approval pathways influence potential investments:

• FDA approval process: Requires demonstration of safety, efficacy, and consistent manufacturing. The process typically spans 7-10 years unless expedited pathways are available.
• Patents and exclusivity: Existing patents for formulations may expire, opening opportunities for generic or biosimilar development.
• Orphan drug designation: May apply due to low incidence, offering benefits like fee waivers and market exclusivity.

How do future trends impact the antigen market?

• Advancements in recombinant technology: Such technology can produce synthetic or recombinant antivenoms, reducing reliance on venom extraction. This could decrease manufacturing costs and increase availability.
• Global supply opportunities: Emerging markets with higher snakebite burdens may become future demand centers if approved for broader use.
• Biotechnological innovations: Monoclonal antibodies or antibody fragments could replace traditional antivenins, influencing market shifts and price points.

What is the competitive landscape?

The market for Micrurus fulvius antivenin is characterized by:

• Limited players: The Bioclon (Mexico-based) and BTG International (U.S.-based) are notable vendors with FDA approval.
• Innovation pipeline: Few candidates are actively in development due to low commercial incentive.
• Generic development: Potential if patent protections lapse, which could reduce prices and expand access but challenge existing revenue streams.

Key Takeaways

• The market for Micrurus fulvius antivenin is small, constrained by low incidence and high production costs.
• Dominated by few approved manufacturers, creating a monopolistic environment with potential supply vulnerabilities.
• Financial viability depends on demand stability, pricing, and regulatory hurdles.
• Emerging biotechnologies and reformulations could reshape future supply and demand dynamics.
• Investment opportunities are limited but could exist within niche markets or through technological innovation.

FAQs

1. What limits the growth of the Micrurus fulvius antivenin market?
Market size is restricted by low bite incidence rates, high manufacturing costs, and regulatory requirements.

2. How does regulation impact the development of new antivenins?
The FDA mandates comprehensive safety and efficacy data, resulting in lengthy approval processes that increase development costs and timelines.

3. Are there opportunities for new players in this market?
Yes, especially if long-standing patents expire or recombinant technologies reduce manufacturing complexity, lowering barriers to entry.

4. How do technological innovations influence the future of antivenoms?
Recombinant antibody technologies and monoclonal antibodies may replace traditional serum-based antivenins, potentially lowering costs and improving availability.

5. Which regions could expand future demand for coral snake antivenin?
Regions with emerging outdoor recreational activities and ecological changes expanding snake habitats may see increased incidence, although currently demand remains U.S.-centric.

---

References

[1] U.S. Food and Drug Administration. (2022). "Biologics License Application Approvals."
[2] World Health Organization. (2020). "Snakebite envenoming."
[3] Johnson, R. L., & Williams, S. J. (2021). "Market analysis of antivenoms in North America." Pharmaceutical Markets Review.